Related Experiment Video
Updated: May 15, 2026
Analysis of Lymph Node Volume by Ultra-High-Frequency Ultrasound Imaging in the Braf/Pten Genetically Engineered Mouse Model of Melanoma
Published on: September 8, 2021
Dabrafenib and its potential for the treatment of metastatic melanoma
Alexander M Menzies1, Georgina V Long, Rajmohan Murali
1Melanoma Institute Australia, Sydney, New South Wales, Australia.
Abstract:
The purpose of this study is to review the development of BRAF inhibitors, with emphasis on the trials conducted with dabrafenib (GSK2118436) and the evolving role of dabrafenib in treatment for melanoma patients. Fifty percent of cutaneous melanomas have mutations in BRAF, resulting in elevated activity of the mitogen-activated protein kinase signaling pathway. Dabrafenib inhibits the mutant BRAF (BRAF(mut)) protein in melanomas with BRAF(V600E) and BRAF(V600K) genotypes. BRAF(V600E) metastatic melanoma patients who receive dabrafenib treatment exhibit high clinical response rates and compared with dacarbazine chemotherapy, progression-free survival. Efficacy has also been demonstrated in BRAF(V600K) patients and in those with brain metastases. Dabrafenib has a generally mild and manageable toxicity profile. Cutaneous squamous cell carcinomas and pyrexia are the most significant adverse effects. Dabrafenib appears similar to vemurafenib with regard to efficacy but it is associated with less toxicity. It is expected that new combinations of targeted drugs, such as the combination of dabrafenib and trametinib (GSK1120212, a MEK inhibitor), will provide higher response rates and more durable clinical benefit than dabrafenib monotherapy.
Insights
Dabrafenib effectively treats melanoma with BRAF mutations, showing high response rates and improved survival. This BRAF inhibitor offers a manageable side effect profile and potential for combination therapies.
Area of Science:
- Oncology
- Pharmacology
- Molecular Biology
Background:
- Fifty percent of cutaneous melanomas harbor BRAF mutations, leading to hyperactive mitogen-activated protein kinase signaling.
- BRAF mutations, specifically BRAF(V600E) and BRAF(V600K), are key drivers in melanoma development.
- Targeting these mutations represents a significant advancement in melanoma treatment.
Purpose of the Study:
- To review the development of BRAF inhibitors.
- To emphasize clinical trials of dabrafenib (GSK2118436).
- To explore the evolving role of dabrafenib in melanoma patient treatment.
Main Methods:
- Review of clinical trial data for dabrafenib.
- Analysis of dabrafenib's efficacy in BRAF(V600E) and BRAF(V600K) melanoma.
- Comparison of dabrafenib with dacarbazine chemotherapy and vemurafenib.
Main Results:
- Dabrafenib demonstrated high clinical response rates and improved progression-free survival in BRAF(V600E) metastatic melanoma patients compared to dacarbazine.
- Efficacy was also observed in BRAF(V600K) patients and those with brain metastases.
- Dabrafenib exhibits a mild and manageable toxicity profile, with cutaneous squamous cell carcinomas and pyrexia as notable adverse effects. It shows comparable efficacy to vemurafenib but with less toxicity.
Conclusions:
- Dabrafenib is an effective BRAF inhibitor for melanoma patients with specific BRAF mutations.
- Combination therapies, such as dabrafenib with trametinib (a MEK inhibitor), are anticipated to enhance response rates and clinical benefit duration.
- Dabrafenib represents a valuable targeted therapy option for melanoma, with ongoing research into optimized treatment strategies.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:38Mitogens and the Cell Cycle